title: Sequential transcription factor targeting for diffuse large B-cell lymphomas.
abstract: Transcription factors play a central role in malignant transformation by activating or repressing waves of downstream target genes. Therapeutic targeting of transcription factors can reprogram cancer cells to lose their advantages in growth and survival. The BCL6 transcriptional repressor plays a central role in the pathogenesis of diffuse large B-cell lymphomas (DLBCL) and controls downstream checkpoints, including the p53 tumor suppressor gene. We report that a specific inhibitor of BCL6 called BPI can trigger a p53 response in DLBCL cells. This was partially due to induction of p53 activity and partially due to relief of direct repression by BCL6 of p53 target genes. BPI could thus induce a p53-like response even in the presence of mutant p53. Moreover, sequential BCL6 peptide inhibitors followed by p53 peptide or small-molecule activators provided a more powerful antilymphoma effect than either treatment alone by maximally restoring p53 target gene expression. Therefore, tandem targeting of the overlapping BCL6 and p53 transcriptional programs can correct aberrant survival pathways in DLBCL and might provide an effective therapeutic approach to lymphoma therapy.
authors.affiliation: Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
authors.forename: Leandro C
authors.initials: LC
authors.lastname: Cerchietti
authors.forename: Jose M
authors.initials: JM
authors.lastname: Polo
authors.forename: Gustavo F
authors.initials: GF
authors.lastname: Da Silva
authors.forename: Pedro
authors.initials: P
authors.lastname: Farinha
authors.forename: Rita
authors.initials: R
authors.lastname: Shaknovich
authors.forename: Randy D
authors.initials: RD
authors.lastname: Gascoyne
authors.forename: Steven F
authors.initials: SF
authors.lastname: Dowdy
authors.forename: Ari
authors.initials: A
authors.lastname: Melnick
mesh_terms: D000595:Amino Acid Sequence; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors*; D016503:Drug Delivery Systems / Q000379:methods*; D004357:Drug Synergism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D051560:Proto-Oncogene Proteins c-bcl-6; D015398:Signal Transduction / Q000187:drug effects*; D014157:Transcription Factors / Q000037:antagonists & inhibitors*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D000970:Antineoplastic Agents; C084103:BCL6 protein, human; C529369:BPI peptide; D004268:DNA-Binding Proteins; D010446:Peptide Fragments; D010455:Peptides; D051560:Proto-Oncogene Proteins c-bcl-6; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53